Rebecca B. Robertson - Nov 1, 2021 Form 4 Insider Report for TANDEM DIABETES CARE INC (TNDM)

Role
Director
Signature
s/ David B. Berger, Attorney-in-Fact for Rebecca B. Robertson
Stock symbol
TNDM
Transactions as of
Nov 1, 2021
Transactions value $
-$128,313
Form type
4
Date filed
11/3/2021, 04:53 PM
Previous filing
Aug 3, 2021
Next filing
Feb 3, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TNDM Common Stock Options Exercise $37.7K +1.11K +282.65% $34.00 1.5K Nov 1, 2021 Direct F1
transaction TNDM Common Stock Sale -$166K -1.22K -81.47% $135.64 278 Nov 1, 2021 Direct F2, F3
transaction TNDM Common Stock Sale -$37.9K -278 -100% $136.35 0 Nov 1, 2021 Direct F2, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TNDM Stock Option Options Exercise $37.7K +1.11K +3.28% $34.00 34.9K Nov 1, 2021 Common Stock 1.11K $34.00 Direct F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon exercise of a stock option award.
F2 The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on May 26, 2021.
F3 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $135.05 to $136.04. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F4 The price reported reflects the weighted average price per share of multiple transactions with prices per share ranging between $136.19 to $136.53. The Reporting Person undertakes to provide the Securities and Exchange Commission (the "SEC"), the issuer, and any security holder full information regarding the number of shares and the prices at which the shares were sold.
F5 The option shall vest in 36 equal monthly installments from January 2, 2019, subject to the terms of Tandem Diabetes Care, Inc. 2013 Stock Incentive Plan, as amended, and the agreements related thereto (the "2013 Plan").
F6 The expiration date for these options is 10 years from the date of grant.